There were 760 press releases posted in the last 24 hours and 171,123 in the last 365 days.

HPAPI 2020 conference to discuss containment solutions and ADC developments

Highly Potent Active Pharmaceutical Ingredients 2020

Highly Potent Active Pharmaceutical Ingredients 2020

The Highly Potent Active Pharmaceutical Ingredients conference will explore real-world examples of PBD payload synthesis and manufacture of oncology products.

LONDON, UNITED KINGDOM, February 10, 2020 / -- On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference.

The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:

1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs
• The manufacture of highly potent ADCs - challenges and solutions
• Deciding when to outsource and when to keep in-house
• Bayer’s ADC production concept
• Best practices for CMO selection and outsourcing ADC development and manufacture
• The journey from development to launch - understanding the needs, solutions, risks and mitigations
Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment – a Case Study
• Innovative solutions to dealing with increasing toxicity of ADCs
• Designing ADC containment systems
• The containment of ADCs – a case study from AZ
Presented by Peter Marshall, Associate Engineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo
• New Product Introduction
• Cross Contamination Risk Assessment & Environmental Risk Assessment
• Case Study: ADC Manufacturing
Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals

Interested parties can view the full agenda and register for the event online at

--- END ---

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
e workshop day: 13th May 2020
London, UK
Sponsored by: BSP Pharmaceuticals
To sponsor or exhibit at the conference, please contact Alia Malick on +44 (0) 207 827 6748

For all delegate enquiries, contact Dylan Brohm on +44 (0) 20 7827 1024.

Neill Howard
SMi Group Ltd
+44 20 7827 6000
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.